2-(5-((4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid

ID: ALA398538

Chembl Id: CHEMBL398538

PubChem CID: 1202786

Max Phase: Preclinical

Molecular Formula: C15H9NO4S2

Molecular Weight: 331.37

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C1NC(=S)S/C1=C/c1ccc(-c2ccccc2C(=O)O)o1

Standard InChI:  InChI=1S/C15H9NO4S2/c17-13-12(22-15(21)16-13)7-8-5-6-11(20-8)9-3-1-2-4-10(9)14(18)19/h1-7H,(H,18,19)(H,16,17,21)/b12-7+

Standard InChI Key:  OTBNRWGTJUMXPA-KPKJPENVSA-N

Alternative Forms

  1. Parent:

    ALA398538

    CK2/Pim1-IN-1

Associated Targets(Human)

PTP4A3 Tchem Protein-tyrosine phosphatase 4A3 (173 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PTP4A2 Tchem Protein tyrosine phosphatase type IVA 2 (36 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PTP4A1 Tchem Protein tyrosine phosphatase type IVA 1 (47 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HEK293 (82097 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 331.37Molecular Weight (Monoisotopic): 330.9973AlogP: 3.13#Rotatable Bonds: 3
Polar Surface Area: 79.54Molecular Species: ACIDHBA: 5HBD: 2
#RO5 Violations: HBA (Lipinski): 5HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 3.32CX Basic pKa: CX LogP: 3.02CX LogD: -2.23
Aromatic Rings: 2Heavy Atoms: 22QED Weighted: 0.66Np Likeness Score: -1.38

References

1. Park H, Jung SK, Jeong DG, Ryu SE, Kim SJ..  (2008)  Discovery of novel PRL-3 inhibitors based on the structure-based virtual screening.,  18  (7): [PMID:18358718] [10.1016/j.bmcl.2008.03.013]
2. Hoeger B, Diether M, Ballester PJ, Köhn M..  (2014)  Biochemical evaluation of virtual screening methods reveals a cell-active inhibitor of the cancer-promoting phosphatases of regenerating liver.,  88  [PMID:25159123] [10.1016/j.ejmech.2014.08.060]
3. Tasker NR, Rastelli EJ, Burnett JC, Sharlow ER, Lazo JS, Wipf P..  (2019)  Tapping the therapeutic potential of protein tyrosine phosphatase 4A with small molecule inhibitors.,  29  (16): [PMID:31307888] [10.1016/j.bmcl.2019.06.048]

Source